St. John's wort modulates the toxicities and pharmacokinetics of CPT-11 (Irinotecan) in rats

Pharmaceutical Research

Volumn 22, Issue 6, 2005, Pages 902-914

  Hu, Zeping ^a   Yang, Xiaoxia ^a   Ho, Paul Chi Liu ^a   Chan, Eli ^a   Sui, Yung Chan ^a   Xu, Congjian ^b   Li, Xiaotian ^b   Zhu, Yi Zhun ^c   Duan, Wei ^c   Chen, Xiao ^d   Huang, Min ^d   Yang, Hongyuan ^c   Zhou, Shufeng ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b FUDAN UNIVERSITY   (China)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

CPT 11; Pharmacokinetics; St. John's wort; Toxicity

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; HYPERICUM PERFORATUM EXTRACT; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; DRUG EFFECT; GASTROINTESTINAL TOXICITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BLOOD CELL COUNT; BODY WEIGHT; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIARRHEA; DRUG INTERACTIONS; HALF-LIFE; HYPERICUM; INTESTINAL DISEASES; INTESTINAL MUCOSA; MALE; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS;

EID: 21244472720     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11095-005-4585-0     Document Type: Article

References (105)

1. M. R. Redinbo L. Stewart P. Kuhn J. J. Champoux W. G. Hol 1998 Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA Science 279 1504 1513
2. L. Stewart M. R. Redinbo X. Qiu W. Hol J. J. Champoux 1998 A model for the mechanism of human topoisomerase I Science 279 1534 1541
3. F. Goldwasser T. Shimizu J. Jackman Y. Hoki P. M. O'Connor K. W. Kohn Y. Pommier 1996 Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells Cancer Res. 56 4430 4437
4. T. Kunimoto K. Nitta T. Tanaka N. Uehara H. Baba M. Takeuchi T. Yokokura S. Sawada T. Miyasaka M. Mutai 1987 Antitumor activity of 7-ethyl-10-[4-(1- piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors Cancer Res. 47 5944 5947
5. P. J. Houghton P. J. Cheshire J. C. Hallman M. C. Bissery A. Mathieu-Boue J. A. Houghton 1993 Therapeutic efficacy of thetopoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1- piperidino)-carbonyloxy-camptothecin against human tumor xenografts:lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10- hydroxycamptothecin Cancer Res. 53 2823 2829
6. M. Potmesil 1994 Camptothecins: from bench research to hospital wards Cancer Res. 54 1431 1439
7. K. Ota R. Ohno S. Shirakawa T. Masaoka K. Okada Y. Ohashi T. Taguchi 1994 Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies Gan To Kagaku Ryoho 21 1047 1055
8. Y. Shimizu S. Umezawa K. Hasumi 1996 Successful treatment of clear cell adenocarcinoma of the ovary (OCCA) with a combination of CPT-11 and mitomycin C Gan To Kagaku Ryoho 23 587 593
9. C. F. Verschraegen T. Levy A. P. Kudelka E. Llerena K. Ende R. S. Freedman C. L. Edwards M. Hord M. Steger A. L. Kaplan 1997 Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix J. Clin. Oncol. 15 625 631
10. W. P. Irvin F. V. Price H. Bailey M. Gelder R. Rosenbluth H. J. Durivage R. K. Potkul 1998 A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix Cancer 82 328 333
11. S. Kudoh Y. Fujiwara Y. Takada H. Yamamoto A. Kinoshita Y. Ariyoshi K. Furuse M. Fukuoka 1998 Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group J. Clin. Oncol. 16 1068 1074
12. T. Tsuji N. Kaneda K. Kado T. Yokokura T. Yoshimoto D. Tsuru 1991 CPT-11 converting enzyme from rat serum: purification and some properties J. Pharmacobio-dyn. 14 341 349
13. T. Satoh M. Hosokawa R. Atsumi W. Suzuki H. Hakusui E. Nagai 1994 Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase Biol. Pharm. Bull. 17 662 664
14. L. P. Rivory M. R. Bowles J. Robert S. M. Pond 1996 Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase Biochem. Pharmacol. 52 1103 1111
15. R. Humerickhouse K. Lohrbach L. Li W. F. Bosron M. E. Dolan 2000 Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2 Cancer Res. 60 1189 1192
16. S. Bencharit C. L. Morton E. L. Howard-Williams M. K. Danks P. M. Potter M. R. Redinbo 2002 Structural insights into CPT-11 activation by mammalian carboxylesterases Nat. Struct. Biol. 9 337 342
17. T. Itoh I. Takemoto S. Itagaki K. Sasaki T. Hirano K. Iseki 2004 Biliary excretion of irinotecan and its metabolites J. Pharm. Pharm. Sci. 7 13 18
18. Y. Kawato M. Aonuma Y. Hirota H. Kuga K. Sato 1991 Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11 Cancer Res. 51 4187 4191
19. R. H. Mathijssen R. J. van Alphen J. Verweij W. J. Loos K. Nooter G. Stoter A. Sparreboom 2001 Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) Clin. Cancer Res. 7 2182 2194
20. A. Santos S. Zanetta T. Cresteil A. Deroussent F. Pein E. Raymond L. Vernillet M. L. Risse V. Boige A. Gouyette 2000 Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans Clin. Cancer Res. 6 2012 2020
21. K. Arimori N. Kuroki A. Kumamoto N. Tanoue M. Nakano E. Kumazawa A. Tohgo M. Kikuchi 2001 Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents Pharm. Res. 18 814 822
22. N. Hanioka S. Ozawa H. Jinno M. Ando Y. Saito J. Sawada 2001 Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin Xenobiotica 31 687 699
23. L. P. Rivory J. F. Riou M. C. Haaz S. Sable M. Vuilhorgne A. Commercon S. M. Pond J. Robert 1996 Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients Cancer Res. 56 3689 3694
24. L. P. Rivory M. C. Haaz P. Canal F. Lokiec J. P. Armand J. Robert 1997 Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials Clin. Cancer Res. 3 1261 1266
25. M. C. Haaz L. Rivory C. Riche L. Vernillet J. Robert 1998 Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions Cancer Res. 58 468 472
26. A. Santos S. Zannetta T. Cresteil 2000 Metabolism of action of camptothecin Ann. N.Y. Acad. Sci. 922 1 10
27. C. Farabos M. C. Haaz P. Gires J. Robert 2001 Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver J. Pharm. Sci. 90 722 731
28. E. Gupta T. M. Lestingi R. Mick J. Ramirez E. E. Vokes M. J. Ratain 1994 Metabolic fate of irinotecan in humans: correlationof glucuronidation with diarrhea Cancer Res. 54 3723 3725
29. Y. Sugiyama Y. Kato X. Chu 1998 Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein Cancer Chemother. Pharmacol. 42 S44 S49
30. D. Gandia D. Abigerges J. P. Armand G. Chabot L. Da Costa M. De Forni A. Mathieu-Boue P. Herait 1993 CPT-11-induced cholinergic effects in cancer patients J. Clin. Oncol. 11 196 197
31. J. R. Hecht 1998 Gastrointestinal toxicity or irinotecan Oncology (Huntingt) 12 72 78
32. L. F. Liu S. D. Desai T. K. Li 2000 Mechanism of action of camptothecin Ann. N.Y. Acad. Sci. 922 1 10
33. Y. Xu M. A. Villalona-Calero 2002 Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity Ann. Oncol. 13 1841 1851
34. S. Kornblau A. B. Benson R. Catalano R. E. Champlin C. Engelking M. Field C. Ippoliti H. M. Lazarus E. Mitchell J. Rubin 2000 Management of cancer treatment-related diarrhea. Issues and therapeutic strategies J. Pain Symptom Manag. 19 118 129
35. H. Sakai T. Sato N. Hamada M. Yasue A. Ikari B. Kakinoki N. Takeguchi 1997 Thromboxane A2, released by the anti-tumour drug irinotecan, is a novel stimulator of Cl-secretion in isolated rat colon J. Physiol. 505 Pt. 1 133 144
36. T. Suzuki H. Sakai A. Ikari 2000 Inhibition of thromboxane A2-induced Cl-secretion by antidiarrhea drug loperamide inisolated rat colon J. Pharmacol. Exp. Ther. 295 233 238
37. F. Saliba R. Hagipantelli J. L. Misset G. Bastian G. Vassal M. Bonnay P. Herait C. Cote M. Mahjoubi D. Mignard 1998 Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment J. Clin. Oncol. 16 2745 2751
38. T. Ikegami L. Ha K. Arimori P. Latham K. Kobayashi S. Ceryak Y. Matsuzaki B. Bouscarel 2002 Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea Cancer Res. 62 179 187
39. H. Shinohara J. J. Killion H. Kuniyasu R. Kumar I. J. Fidler 1998 Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002 Clin. Cancer Res. 4 2053 2063
40. K. Takasuna T. Hagiwara M. Hirohashi M. Kato M. Nomura E. Nagai T. Yokoi T. Kamataki 1998 Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats Cancer Chemother. Pharmacol. 42 280 286
41. D. F. Kehrer A. Sparreboom J. Verweij P. de Bruijn C. A. Nierop J. van de Schraaf E. J. Ruijgrok M. J. de Jonge 2001 Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients Clin. Cancer Res. 7 1136 1141
42. M. Prados J. Kuhn W. Yung 2001 A phase-I study of CPT-11 given every 3 weeks to patients with recurrent malignant glioma. A North American Brain Tumor Consortium (NABTC) study Proc. -Am. Soc. Clin. Oncol. 19 162
43. E. Gupta A. Safa X. Wang M. Ratain 1996 Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A Cancer Res. 56 1309 1314
44. M. Ratain 2000 Insights into the pharmacokinetics and pharmacodynamics of irinotecan Clin. Cancer Res. 6 3393 3394
45. O. C. Trifan W. F. Durham V. S. Salazar J. Horton B. D. Levine B. S. Zweifel T. W. Davis J. L. Masferrer 2002 Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11 Cancer Res. 62 5778 5784
46. M. Horikawa Y. Kato Y. Sugiyama 2002 Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats Pharm. Res. 19 1345 1353
47. M. Horikawa Y. Kato Y. Sugiyama 2002 Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats Pharm. Res. 19 1345 1353
48. G. Di Carlo F. Borrelli E. Ernst A. A. Izzo 2001 St. John's wort: prozac from the plant kingdom Trends Pharmacol. Sci. 22 292 297
49. A. R. Bilia S. Gallori F. F. Vincieri 2002 St. John's wort and depression: efficacy, safety and tolerability-an update Life Sci. 70 3077 3096
50. V. Schulz 2002 Clinical trials with hypericum extracts in patients with depression-results, comparisons, conclusions for therapy with antidepressant drugs Phytomedicine 9 468 474
51. E. Ernst 1999 Second thoughts about safety of St. John's wort Lancet 354 2014 2016
52. A. Johne J. Brockmoller S. Bauer A. Maurer M. Langheinrich I. Roots 1999 Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum) Clin. Pharmacol. Ther. 66 338 345
53. D. Durr B. Stieger G. A. Kullak-Ublick K. M. Rentsch H. C. Steinert P. J. Meier K. Fattinger 2000 St. John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4 Clin. Pharmacol. Ther. 68 598 604
54. L. B. Moore B. Goodwin S. A. Jones G. B. Wisely C. J. Serabjit-Singh T. M. Willson 2000 St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor Proc. Natl. Acad. Sci. USA 97 7500 7502
55. S. C. Piscitelli A. H. Burstein D. Chaitt R. M. Alfaro J. Falloon 2000 Indinavir concentrations and St. John's wort Lancet 355 547 548
56. C. A. Roby G. D. Anderson E. Kantor D. A. Dryer A. H. Burstein 2000 St. John's wort: effect on CYP3A4 activity Clin. Pharmacol. Ther. 67 451 457
57. F. Ruschitzka P. J. Meier M. Turina T. F. Luscher G. Noll 2000 Acute heart transplant rejection due to Saint John's wort Lancet 355 548 549
58. J. M. Wentworth M. Agostini J. Love J. W. Schwabe V. K. Chatterjee 2000 St. John's wort, a herbal antidepressant, activates the steroid X receptor J. Endocrinol. 166 R11 R16
59. B. Goodwin L. B. Moore C. M. Stoltz D. D. McKee S. A. Kliewer 2001 Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor Mol. Pharmacol. 60 427 431
60. Z. Q. Wang C. Gorski M. A. Hamman S. M. Huang L. J. Lesko S. D. Hall 2001 The effects of St. John's wort (Hypericum Perforatum) on human cytochrome P450 activity Clin. Pharmacol. Ther. 70 317 326
61. A. Johne J. Schmider J. Brockmoller A. M. Stadelmann E. Stormer S. Bauer G. Scholler M. Langheinrich I. Roots 2002 Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum) J. Clin. Psychopharmacol. 22 46 54
62. Z. Wang M. A. Hamman S. M. Huang L. J. Lesko S. D. Hall 2002 Effect of St. John's wort on the pharmacokinetics of fexofenadine Clin. Pharmacol. Ther. 71 414 420
63. A. A. Izzo 2004 Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence Int. J. Clin. Pharmacol. Ther. 42 139 148
64. S. Zhou E. Chan S. Q. Pan M. Huang E. J. Lee 2004 Pharmacokinetic interactions of drugs with St. John's wort J. Psychopharmacol. 18 262 276
65. R. H. Mathijssen J. Verweij P. de Bruijn W. J. Loos A. Sparreboom 2002 Effects of St. John's wort on irinotecan metabolism J. Natl. Cancer Inst. 94 1247 1249
66. A. Kurita S. Kado N. Kaneda M. Onoue S. Hashimoto T. Yokokura 2003 Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion Cancer Chemother. Pharmacol. 52 349 360
67. A. Kurita S. Kado N. Kaneda M. Onoue S. Hashimoto T. Yokokura 2000 Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats Cancer Chemother. Pharmacol. 46 211 220
68. M. Miampamba E. J. Parr D. M. McCafferty J. L. Wallace K. A. Sharkey 1998 Effect of intracolonic benzalkonium chloride on trinitrobenzene sulphonic acid-induced colitis in the rat Aliment Pharmacol. Ther. 12 219 228
69. M. Kruschewski T. Foitzik A. Perez-Canto A. Hubotter H. J. Buhr 2001 Changes of colonic mucosal microcirculation and histology in two colitis models: an experimental study using intravital microscopy and a new histological scoring system Dig. Dis. Sci. 46 2336 2343
70. I. Maric L. Poljak S. Zoricic D. Bobinac D. Bosukonda K. T. Sampath S. Vukicevic 2003 Bone morphogenetic protein-7 reduces the severity of colon tissue damage and accelerates the healing of inflammatory bowel disease in rats J. Cell. Physiol. 196 258 264
71. A. Sparreboom P. de Bruijn M. J. de Jonge W. J. Loos G. Stoter J. Verweij K. Nooter 1998 Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces J. Chromatogr., B, Biomed. Sci. Appl. 712 225 235
72. J. Escoriaza A. Aldaz C. Castellanos E. Calvo J. Giraldez 2000 Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies J. Chromatogr., B, Biomed. Sci. Appl. 740 159 168
73. S. Poujol F. Pinguet F. Malosse C. Astre M. Ychou S. Culine F. Bressolle 2003 Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies Clin. Chem. 49 1900 1908
74. D. Durr B. Stieger G. A. Kullak-Ublick K. M. Rentsch H. C. Steinert P. J. Meier K. Fattinger 2000 St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4 Clin. Pharmacol. Ther. 68 598 604
75. Y. Shibayama R. Ikeda T. Motoya K. Yamada 2004 St. John's Wort (Hypericum perforatum) induces overexpression of multidrug resistance protein 2 (MRP2) in rats: a 30-day ingestion study Food Chem. Toxicol. 42 995 1002
76. M. L. Wong, F. O'Kirwan, J. P. Hannestad, K. J. Irizarry, D. Elashoff, and J. Licinio. St. John's wort and imipramine-induced gene expression profiles identify cellular functions relevant to antidepressant action and novel pharmacogenetic candidates for the phenotype of antidepressant treatment response. Mol Psychiatry in press (2004).
77. O. C. Trifan W. F. Durham V. S. Salazar J. Horton B. D. Levine B. S. Zweifel T. W. Davis J. L. Masferrer 2002 Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11 Cancer Res. 62 5778 5784
78. K. Arimori N. Kuroki M. Hidaka T. Iwakiri K. Yamsaki M. Okumura H. Ono N. Takamura M. Kikuchi M. Nakano 2003 Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats Pharm. Res. 20 910 917
79. B. Chowbay A. Sharma Q. Y. Zhou Y. B. Cheung E. J. Lee 2003 The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents Oncol. Rep. 10 745 751
80. A. Kurita S. Kado N. Kaneda M. Onoue S. Hashimoto T. Yokokura 2003 Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion Cancer Chemother. Pharmacol. 52 349 356
81. J. F. Pizzolato L. B. Saltz 2003 The camptothecins Lancet 361 2235 2242
82. M. D. DeMario M. J. Ratain 1998 Oral chemotherapy-Rationale and future directions J. Clin. Oncol. 16 2557 2567
83. F. A. Greco 1998 Evolving role of oral chemotherapy for the treatment of patients with neoplasms Oncology 12 43 50
84. J. M. M. Terwogt J. H. M. Schellens W. W. T. Huinink J. H. Beijnen 1999 Clinical pharmacology of anticancer agents in relation to formulations and administration routes Cancer Treat. Rev. 25 83 101
85. C. F. Stewart W. C. Zamboni W. R. Crom P. J. Houghton 1997 Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice Cancer Chemother. Pharmacol. 40 259 265
86. W. C. Zamboni P. J. Houghton J. Thompson P. J. Cheshire S. K. Hanna L. B. Richmond X. Lou C. F. Stewart 1998 Altered irinotecan and SN-38 disposition after intravenous andoral administration of irinotecan in mice bearing human neuroblastoma xenografts Clin. Cancer Res. 4 455 462
87. R. L. Drengler J. G. Kuhn L. J. Schaaf G. I. Rodriguez M. A. Villalona-Calero L. A. Hammond J. A. Stephenson Jr S. Hodges M. A. Kraynak B. A. Staton 1999 Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors J. Clin. Oncol. 17 685 696
88. C. F. Stewart M. Leggas J. D. Schuetz J. C. Panetta P. J. Cheshire J. Peterson N. Daw J. J. Jenkins III R. Gilbertson G. S. Germain 2004 Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice Cancer Res. 64 7491 7499
89. N. E. Schoemaker I. E. Kuppens W. W. Huinink P. Lefebvre J. H. Beijnen S. Assadourian G. J. Sanderink J. H. Schellens 2005 Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours Cancer Chemother. Pharmacol. 55 263 270
90. O. Soepenberg H. Dumez J. Verweij D. Semiond M. J. Dejonge F. A. Eskens J. T. Steeg J. Selleslach S. Assadourian G. J. Sanderink 2005 Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors J. Clin. Oncol. 23 889 898
91. J. S. Markowitz C. L. DeVane D. W. Boulton S. W. Carson Z. Nahas S. C. Risch 2000 Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers Life Sci. 66 PL133 PL139
92. J. S. Markowitz J. L. Donovan C. L. DeVane R. M. Taylor Y. Ruan J. S. Wang K. D. Chavin 2003 Effect of St. John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme JAMA 290 1500 1504
93. X. Y. Chu Y. Kato K. Niinuma K. I. Sudo H. Hakusui Y. Sugiyama 1997 Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats J. Pharmacol. Exp. Ther. 281 304 314
94. X. Y. Chu Y. Kato Y. Sugiyama 1997 Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats Cancer Res. 57 1934 1938
95. X. Y. Chu H. Suzuki K. Ueda Y. Kato S. Akiyama Y. Sugiyama 1999 Active efflux of CPT-11 and its metabolites in human KB-derived cell lines J. Pharmacol. Exp. Ther. 288 735 741
96. M. Yoshikawa Y. Ikegami S. Hayasaka K. Ishii A. Ito K. Sano T. Suzuki T. Togawa H. Yoshida H. Soda 2004 Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells Int. J. Cancer 110 921 927
97. M. Yoshikawa Y. Ikegami K. Sano H. Yoshida H. Mitomo S. Sawada T. Ishikawa 2004 Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid J. Exp. Ther. Oncol. 4 25 35
98. J. Barnes L. A. Anderson J. D. Phillipson 2001 St. John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties J. Pharm. Pharmacol. 53 583 600
99. E. Tedeschi M. Menegazzi D. Margotto H. Suzuki U. Forstermann H. Kleinert 2003 Anti-inflammatory actions of St. John's wort: inhibition of human inducible nitric-oxide synthase expression by down-regulating signal transducer and activator of transcription-1alpha (STAT-1alpha) activation J. Pharmacol. Exp. Ther. 307 254 261
100. P. M. Bork S. Bacher M. L. Schmitz U. Kaspers M. Heinrich 1999 Hypericin as a non-antioxidant inhibitor of NF-kappa B Planta Med. 65 297 300
101. P. Agostinis A. Donella-Deana J. Cuveele A. Vandenbogaerde S. Sarno W. Merlevede P. de Witte 1996 A comparative analysis of the photosensitized inhibition of growth-factor regulated protein kinases by hypericin-derivatives Biochem. Biophys. Res. Commun. 220 613 617
102. B. L. Fiebich A. Hollig K. Lieb 2001 Inhibition of substance P-induced cytokine synthesis by St. John's wort extracts Pharmacopsychiatry 34 S26 S28
103. G. M. Raso R. Meli G. Di Carlo M. Pacilio R. Di Carlo 2001 Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A. 1 Life Sci. 68 921 931
104. G. M. Raso M. Pacilio G. Di Carlo E. Esposito L. Pinto R. Meli 2002 In-vivo and in-vitro anti-inflammatory effect of Echinacea purpurea and Hypericum perforatum J. Pharm. Pharmacol. 54 1379 1383
105. E. Tedeschi M. Menegazzi D. Margotto H. Suzuki U. Forstermann H. Kleinert 2003 Anti-inflammatory actions of St. John's wort: inhibition of human inducible nitric-oxide synthase expression by down-regulating signal transducer and activator of transcription-1alpha (STAT-1alpha) activation J.Pharmacol. Exp. Ther. 307 254 261